Clinical Trial: 8951-CL-0103

Trial Status: Open
Disease Type: Esophageal/Gastric
Trial ID 8951-CL-0103
Sponsor ID 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Principal Investigator
Timothy A. McCarthy, MD


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID ARC-21
Sponsor ID Arcus Biosciences

A safety and efficacy study of domvanalimab + zimberelimab combination therapy with and without chemotherapy in adult participants with advanced upper gastrointestinal tract malignancies

Principal Investigator
Keeran R. Sampat, MD
Trial ID D910GC00001
Sponsor ID Matterhorn

A Randomized, Double Blind, Placebo-Controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy in Patients with Resectable Gastric and GE Junction Cancer